Alternative Model-Based Translational Drug Development
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".
Deadline for manuscript submissions: closed (31 December 2024) | Viewed by 2957
Special Issue Editors
Interests: pharmacology; cardio-renal pharmacology; medicinal plants; ethnopharmacology; hepatic diseases; metabolic diseases
Interests: antihypertensive; antiatherogenic; cardioprotective; diuretic; lipid-lowering; vasodilator
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The quest for effective and safe drug delivery systems has been a driving force in pharmaceutical research. Delivering medications efficiently and accurately to their intended targets is crucial for maximizing therapeutic outcomes while minimizing adverse effects. Recently, there has been a growing emphasis on exploring innovative and alternative models to revolutionize drug delivery. Traditional approaches to drug delivery have often faced challenges, such as limited efficacy, poor bioavailability, and off-target effects. These limitations have prompted researchers and scientists to explore new avenues for drug delivery that can overcome these hurdles and provide improved therapeutic options for patients. One area that has gained significant attention is the intersection between drug formulation and translational medicine. Translational medicine bridges the gap between laboratory discoveries and their practical application in clinical settings. By incorporating translational medicine principles into drug formulation, researchers aim to enhance the development and delivery of pharmaceutical formulations, ultimately leading to better patient outcomes.
This Special Issue aims to shed light on the latest advancements in alternative drug delivery models and their potential implications for translational medicine. We will explore how these innovative approaches can improve the efficiency of drug formulations, promote personalized medicine, and address the specific needs of individual patients. By highlighting the importance of this research area, we aim to inspire further exploration and collaboration among scientists, clinicians, and pharmaceutical experts. Ultimately, our collective efforts in advancing drug delivery systems have the potential to transform the field of medicine, revolutionize treatment approaches, and enhance patient care.
In this Special Issue, original research articles and reviews are welcome. Research areas may include, but are not limited to, the following:
- Recent developments in nanotechnology-based drug delivery systems, including nanoparticles, liposomes, and micelles.
- Alternative models for drug delivery research, such as organoids, microfluidic systems, and computational modeling.
- Bioengineering strategies for personalized medicine, such as 3D printing of drug delivery devices and organs-on-chips.
- Development of patient-specific drug delivery systems, considering factors like genetic variations and disease-specific characteristics.
- Design and evaluation of preclinical models that better mimic human physiology and predict clinical outcomes.
- Development of novel targeting agents and strategies to improve drug accumulation at specific disease sites.
- Case studies on the clinical application of targeted drug delivery systems, highlighting their efficacy and potential impact on patient outcomes.
- Application of alternative models in studying drug transport, absorption, and distribution.
We look forward to receiving your contributions.
Dr. Francislaine Aparecida Dos Reis Lívero
Dr. Arquimedes Gasparotto Junior
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pharmaceutical preparations
- drug compounding
- drug delivery systems
- translation medicine
- alternative models
- preclinical studies
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
